canagliflozin


Also found in: Medical, Wikipedia.
Translations

canagliflozin

n canagliflozina
References in periodicals archive ?
Canagliflozin reduced risk of CV death or HHF by 22%, fatal or hospitalized heart failure (HHF) by 30% , and HHF alone by 33%.
The results indicated that canagliflozin was associated with a significant reduction in risk of cardiovascular death or hospitalisation for heart failure by 22 percent, fatal or hospitalised heart failure by 30 percent; and hospitalisation for heart failure alone by 33 percent.
Results showed that across this broad population of patients with T2D, treatment with an SGLT-2i (Farxiga, empagliflozin, ipragliflozin, canagliflozin, tofogliflozin or luseogliflozin) was associated with a 49% lower risk of ACD, 36% of hHF, 19% of MI and 32% of stroke (p?
Results showed that across this broad population of patients with T2D, treatment with an SGLT-2i - including Farxiga, empagliflozin, ipragliflozin, canagliflozin, tofogliflozin or luseogliflozin - was associated with a 49% lower risk of ACD, 36% of hHF, 19% of MI and 32% of stroke compared to other T2D medicines.
There has been some breakthrough in the management and treatment of this diabetes such as the use of glimepiride, acarbose, alogliptin, canagliflozin, glipizide, glimepiride, empagliflozin, dapagliflozin, colesevelam and sometimes a combination of medication.
115],[116] Dapagliflozin, canagliflozin, and other sodium glucose co-transporter 2 inhibitors can decrease serum urate levels.
FDA Drug Safety Communication: FDA revises label of diabetes drug canagliflozin (Invokana, Invokamet) to include updates on bone fracture risk and new information on decreased bone mineral density, http:// www.
Canagliflozin slows progression of renal function decline independently of glycemic effects.
Canagliflozin (Invokana), dapagliflozin (Farxiga), and empagliflozin (Jardiance) work by inhibiting reabsorption of glucose in the kidney, which results in lower blood glucose.
There are three drugs in this sodium-glucose cotransporter-2 inhibitor subclass: canagliflozin (Invokana), dapagliflozin (Farxiga), and empagliflozin (Jardiance).
SAN DIEGO--Oral, once-daily treatment with canagliflozin significantly reduced the risk of cardiovascular events, compared with placebo, among more than 10,000 patients with type 2 diabetes at high risk of cardiovascular disease.
In a renal endpoints trial of patients at high cardiovascular risk, progression of albuminuria and the renal composite outcome (composed of sustained reduction in eGFR, the need for renal replacement therapy, or death from any cause) occurred less frequently in patients taking canagliflozin (Neal et al.